Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
Objective It has been proved that glucagon-like peptide-1 receptor (GLP1R) agonists have positive effects on renal outcomes in diabetic patients. However, it remains unknown whether GLP1R agonists could provide similar protection against other kidney diseases.Methods We performed two-sample Mendelia...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2478488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850187222676930560 |
|---|---|
| author | Yu-Xuan Yao Chen Tang Feng-Lei Si Ji-Cheng Lv Su-Fang Shi Xu-Jie Zhou Li-Jun Liu Hong Zhang |
| author_facet | Yu-Xuan Yao Chen Tang Feng-Lei Si Ji-Cheng Lv Su-Fang Shi Xu-Jie Zhou Li-Jun Liu Hong Zhang |
| author_sort | Yu-Xuan Yao |
| collection | DOAJ |
| description | Objective It has been proved that glucagon-like peptide-1 receptor (GLP1R) agonists have positive effects on renal outcomes in diabetic patients. However, it remains unknown whether GLP1R agonists could provide similar protection against other kidney diseases.Methods We performed two-sample Mendelian randomization (MR) analyses to determine the causal effects of GLP1R agonists on multiple kidney diseases. Exposure to GLP1R agonist was proxied by the available cis-eQTLs for GLP1R. Primary outcomes included the risk assessment for diabetic nephropathy, IgA nephropathy, membranous nephropathy, nephrotic syndrome, chronic kidney disease, acute glomerulonephritis, chronic glomerulonephritis and calculus of kidney/ureter. Type 2 diabetes and body mass index were used as positive control. Two-stage network MR analyses were conducted to assess the mediation effect of inflammatory proteins on the relationships between GLP1R agonists and kidney diseases.Results After meta-analyses of both discovery and validation cohorts, genetically proxied GLP1R agonist was found to significantly associated with a decreased risk of diabetic nephropathy (OR = 0.72, 95%CI = 0.54–0.97, p = 0.031) and IgA nephropathy (OR = 0.58, 95%CI = 0.36–0.94, p = 0.027). Two-stage network MR revealed that there was an indirect effect of GLP1R agonist on IgA nephropathy through signaling lymphocytic activation molecule family member 1 (SLAMF1), with a mediated proportion of 34.27% (95% CI, 1.47–67.03%, p = 0.041) of the total effect.Conclusions The findings of current study presented genetic proof for the potential protective effects of GLP1R agonists in the development of diabetic nephropathy and IgA nephropathy, offering a novel sight for future mechanistic and clinical applications. |
| format | Article |
| id | doaj-art-8418e8dcdc2a4e129bfe73ccfc1b4dcf |
| institution | OA Journals |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-8418e8dcdc2a4e129bfe73ccfc1b4dcf2025-08-20T02:16:10ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492025-12-0147110.1080/0886022X.2025.2478488Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomizationYu-Xuan Yao0Chen Tang1Feng-Lei Si2Ji-Cheng Lv3Su-Fang Shi4Xu-Jie Zhou5Li-Jun Liu6Hong Zhang7Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, ChinaObjective It has been proved that glucagon-like peptide-1 receptor (GLP1R) agonists have positive effects on renal outcomes in diabetic patients. However, it remains unknown whether GLP1R agonists could provide similar protection against other kidney diseases.Methods We performed two-sample Mendelian randomization (MR) analyses to determine the causal effects of GLP1R agonists on multiple kidney diseases. Exposure to GLP1R agonist was proxied by the available cis-eQTLs for GLP1R. Primary outcomes included the risk assessment for diabetic nephropathy, IgA nephropathy, membranous nephropathy, nephrotic syndrome, chronic kidney disease, acute glomerulonephritis, chronic glomerulonephritis and calculus of kidney/ureter. Type 2 diabetes and body mass index were used as positive control. Two-stage network MR analyses were conducted to assess the mediation effect of inflammatory proteins on the relationships between GLP1R agonists and kidney diseases.Results After meta-analyses of both discovery and validation cohorts, genetically proxied GLP1R agonist was found to significantly associated with a decreased risk of diabetic nephropathy (OR = 0.72, 95%CI = 0.54–0.97, p = 0.031) and IgA nephropathy (OR = 0.58, 95%CI = 0.36–0.94, p = 0.027). Two-stage network MR revealed that there was an indirect effect of GLP1R agonist on IgA nephropathy through signaling lymphocytic activation molecule family member 1 (SLAMF1), with a mediated proportion of 34.27% (95% CI, 1.47–67.03%, p = 0.041) of the total effect.Conclusions The findings of current study presented genetic proof for the potential protective effects of GLP1R agonists in the development of diabetic nephropathy and IgA nephropathy, offering a novel sight for future mechanistic and clinical applications.https://www.tandfonline.com/doi/10.1080/0886022X.2025.2478488Glucagon-like peptide-1 receptor agonistschronic kidney diseasediabetic nephropathyIgA nephropathyMendelian randomization |
| spellingShingle | Yu-Xuan Yao Chen Tang Feng-Lei Si Ji-Cheng Lv Su-Fang Shi Xu-Jie Zhou Li-Jun Liu Hong Zhang Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization Renal Failure Glucagon-like peptide-1 receptor agonists chronic kidney disease diabetic nephropathy IgA nephropathy Mendelian randomization |
| title | Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization |
| title_full | Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization |
| title_fullStr | Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization |
| title_full_unstemmed | Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization |
| title_short | Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization |
| title_sort | glucagon like peptide 1 receptor agonists inflammation and kidney diseases evidence from mendelian randomization |
| topic | Glucagon-like peptide-1 receptor agonists chronic kidney disease diabetic nephropathy IgA nephropathy Mendelian randomization |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2478488 |
| work_keys_str_mv | AT yuxuanyao glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT chentang glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT fengleisi glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT jichenglv glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT sufangshi glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT xujiezhou glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT lijunliu glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization AT hongzhang glucagonlikepeptide1receptoragonistsinflammationandkidneydiseasesevidencefrommendelianrandomization |